Multi-omics analysis unveils a four-gene prognostic signature in esophageal squamous carcinoma and the therapeutic potential of PKP1
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a four-gene signature (CCND1-PKP1-JUP-ANKRD12) to predict esophageal squamous cell carcinoma (ESCC) patient survival. PKP1 also shows potential for gene therapy in multiple cancers.
Area Of Science
- Oncology
- Genomics
- Molecular Biology
Background
- Esophageal squamous cell carcinoma (ESCC) is a heterogeneous malignancy with poor patient outcomes.
- Accurate patient stratification and prognostic markers are essential for effective treatment strategies.
Purpose Of The Study
- To classify ESCC subtypes using integrated single-cell and bulk RNA sequencing.
- To develop a novel gene signature for predicting ESCC prognosis and guiding treatment decisions.
Main Methods
- Integrated single-cell and bulk RNA sequencing (RNA-seq) for ESCC characterization.
- Non-negative matrix factorization (NMF) for patient stratification into subtypes.
- Cox and LASSO regression analyses to construct a four-gene prognostic risk model (CCND1-PKP1-JUP-ANKRD12).
- Validation using RT-qPCR, proteomics, and multiplex immunohistochemistry (mIHC).
Main Results
- Identified four distinct ESCC subtypes with unique cellular features and prognoses.
- The CCND1-PKP1-JUP-ANKRD12 signature accurately predicted patient survival, independent of clinical factors.
- Gene expression correlated with immunoregulatory genes and anti-cancer drug sensitivities.
- PKP1 expression linked to EGFR levels and gene effect scores across various cancers.
Conclusions
- The CCND1-PKP1-JUP-ANKRD12 signature offers a promising tool for ESCC prognosis and diagnosis.
- PKP1 dysregulation presents potential therapeutic targets for gene therapy in multiple cancers.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
